TORNTPHARM Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹3,303 Cr
verified against source
Revenue YoY
18%
reported change
EBITDA
Pending
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Torrent Pharma delivered a robust Q3 FY26 with consolidated revenues of INR 3,303 crore, up 18% YoY, driven by strong branded market performance (75% of revenue). India grew 14% with 5.5% volume outperformance versus IPM's 1.2%, while Brazil delivered 27% growth (13% secondary sales). EBITDA margin expanded to 32.9%. The JB Pharma acquisition closed with 48.8% stake on January 21, with line-by-line consolidation from Q4. Management guided JB margin improvement to 32-33% (from JB's current ~28-29%) and cost synergies of INR 400-450 crore over 2-3 years (20% in year one). Germany remains impacted by third-party supplier disruption (down 6% CC), with resolution unlikely for 3-4 quarters. US sales of $36M up 12% with 5-7 annual launches targeted, aiming to cross $200M annually by FY27. Brazil GLP-1 (Semaglutide) filing awaiting ANVISA approval with priority review status. Key risk: integration execution at JB amid CEO/CFO resignations and Q4 business practice adjustments.
Colored figures show movement against the previous available record.
Guidance to track
- JB's current 28-29% EBITDA margin has significant scope to converge toward Torrent's 32.5-33% base business margin, with synergy realization starting Q4 FY26.
- Management expressed optimism that current US business ($144M annualized) can grow to cross $200M per year by FY27, driven by 5-7 new launches annually and facility clearances.
- Current field force of 6,900 to increase to just over 7,000 by FY26 year-end and approximately 7,500 by end of FY27, enabling continued market share gains.
- Net debt/EBITDA guided at 1.1x in FY28 and 0.6x in FY29 as integration progresses and cash generation accelerates post-JB consolidation.
Risks flagged
- Supply disruption from third-party manufacturer continues with no resolution timeline visible. Europe regulatory interactions between EMA and FDA extending resolution. Alternate supplier identification will take 3-4 quarters minimum.
- Change of control creates business practice adjustments and process integration challenges. Q4 could see muted performance in both India and international JB operations before returning to normal in Q1 FY27.
- Semaglutide filing with ANVISA under priority review but 11-12 competitors in queue. Expected 45-50% price erosion on launch. Approval timing remains at regulator's discretion with no guaranteed launch in Q4.
- CEO and CFO of JB have already resigned. While historical attrition rates maintained post-acquisition announcement, loss of institutional knowledge during transition poses execution risk.
Key quotes
- We have not looked at the revenue synergies yet. We'll wait for first year business top line to stabilize, and then we can look at revenue synergies.
- JB's margin is closer to 28-29% EBITDA margin. I think our margin this year has been in the range of 32.5-33. So there is definitely a scope to bring JB's margin closer to our base business margin in the next financial year.
- Germany revenues have declined by 6%, mainly due to the continued disruption at the third-party supplier. Unfortunately, Damayanti, I cannot give a timeline because our supplier is caught up in regulatory issues.
Research modules